People channel feed

Ex­clu­sive: Charm Ther­a­peu­tic­s' founder steps down as CEO, as AI biotech eyes clin­ic in 2026

Last month
AI

Mur­al On­col­o­gy ends clin­i­cal de­vel­op­ment, lays off most work­ers

Last month
R&D

Re­cruiters say some bio­phar­mas pause hir­ing as they strug­gle to make sense of on­go­ing un­cer­tain­ty

Last month
Startups

Vac­cines, obe­si­ty drugs, job cuts: Take­aways from RFK Jr.'s first net­work in­ter­view as HHS chief

Last month
Pharma

Q&A: Lund­beck’s head of R&D on let­ting ‘bi­ol­o­gy speak’ in neu­ro­science

Last month
R&D

‘This is self-in­flict­ed’: Leerink’s David Risinger on the mar­ket shock and hits to bio­phar­ma

Last month
FDA+

Q&A: A con­ver­sa­tion with GLP-1 co-dis­cov­er­er Jens Ju­ul Holst on the fu­ture of in­cretin-based drugs

Last month

Q&A: David Liu talks about sci­ence un­der pres­sure, teas­es “dis­ease-ag­nos­tic” gene edit­ing

Last month

Re­lay Ther­a­peu­tics does third round of lay­offs in nine months, af­fect­ing about 70 em­ploy­ees

Last month

Sen­ate con­firms Dr. Oz to lead Medicare agency amid HHS over­haul

Last month
Pharma
FDA+

Q&A: John Crow­ley warns biotech is 'dan­ger­ous­ly close' to break­ing, as tar­iff threat, mar­kets bat­ter in­dus­try

Last month
Pharma
FDA+

Ex­clu­sive: Mikael Dol­sten shares his post-Pfiz­er plans, in­clud­ing ad­vis­ing an AI uni­corn with phar­ma dreams

Last month
AI

Arie Bellde­grun nabs two lead­ers for Vi­da Ven­tures amid plans for fourth fund

Last month

‘It’ll be a chal­lenge’: BIO chief Crow­ley ad­dress­es seis­mic FDA over­haul

Last month
Pharma
FDA+

Q&A: Demis Has­s­abis talks 'tur­bocharg­ing' Iso­mor­phic with $600M, ex­pand­ing in­to an­ti­bod­ies and the US

Last month
AI

Fir­ings sweep across FDA as for­mer lead­ers lament the gut­ting of drug agency

Last month
FDA+

Sanofi con­tin­ues its bet on R&D by poach­ing GSK’s head of de­vel­op­ment

Last month
Pharma

What’s next af­ter Marks? At FDA, ques­tions over more top ex­its and fu­ture vi­sion for drug agency

Last month
FDA+

In­spir­na, which was prepar­ing for a Phase 3 can­cer tri­al, has fold­ed

Last month
Startups

El­e­vate­Bio trims work­force by 17%

2 months ago
Startups
Cell/Gene Tx

Covid con­trar­i­an Bhat­tacharya is con­firmed as NIH chief, tak­ing over at a fraught mo­ment for fed­er­al re­search

2 months ago
FDA+

Lyn­dra Ther­a­peu­tics to wind down amid fund­ing hur­dles for long-act­ing drug tech­nol­o­gy

2 months ago
Startups

Sen­ate com­mit­tee backs Dr. Oz's nom­i­na­tion to lead CMS

2 months ago
Pharma

Il­lu­mi­na adds ac­tivist in­vestor to board, taps for­mer FDA head as chair

2 months ago
Diagnostics
First page Previous page 12345 Next page Last page
A service from the Financial Times